Table 1.
Tertiles of Inflammatory Markers |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Overall | C-reactive Protein (ug/ml) | Interleukin-6 (pg/ml) | Tumor Necrosis Factor-α (pg/ml) | |||||||
T1 | T2 | T3 | T1 | T2 | T3 | T1 | T2 | T3 | ||
Total Participants (Cases) | 2323 (89, 4%) | 718 (26, 4%) | 715 (21, 3%) | 716 (39, 5%) | 734 (17, 2%) | 735 (23, 3%) | 734 (46, 6%) | 721 (20, 3%) | 720 (32, 4%) | 720 (28, 4%) |
Exposure, Median(SD) | 5.9 (9.8) | 0.7 (0.6) | 3.1 (0.9) | 19.9 (52.7) | 1.1 (0.3) | 2.0 (0.3) | 5.2 (3.2) | 2.1 (0.4) | 3.1 (0.3) | 5.0 (1.9) |
Age at baseline, mean (SD) | 73.5 (2.9) | 73.5 (2.8) | 73.6 (2.9) | 73.2 (2.8) | 73.2 (2.7) | 73.6 (2.9) | 73.5 (2.9) | 73.3 (2.9) | 73.3 (2.8) | 73.9 (2.9) |
Smoking, Pack-years, mean(SD) | 17.6 (26.7) | 15.1 (24.6) | 19 (27.9) | 19.0 (26.5) | 12.2 (20.5) | 18.6 (29) | 21.9 (28.7) | 15.0 (23.7) | 16.6 (24.2) | 20.8 (30.4) |
Body mass index (kg/m2), mean (SD) | 27.5 (4.9) | 26.1 (4.0) | 27.2 (4.5) | 29.1 (5.4) | 26.1 (4.0) | 27.9 (4.5) | 28.5 (5.5) | 27.1 (5.0) | 27.5 (4.8) | 27.9 (4.8) |
Gender, % Male | 46 | 54 | 49 | 36 | 41 | 49 | 49 | 42 | 46 | 50 |
Race, % Caucasian | 55 | 64 | 61 | 45 | 61 | 57 | 50 | 48 | 59 | 62 |
Site, % Memphis | 50 | 46 | 50 | 50 | 46 | 50 | 53 | 53 | 46 | 49 |
Education % | ||||||||||
Less than High School | 26 | 22 | 24 | 30 | 23 | 26 | 29 | 28 | 23 | 27 |
High School | 33 | 32 | 35 | 34 | 33 | 32 | 34 | 30 | 33 | 37 |
Post-secondary | 41 | 45 | 41 | 36 | 44 | 42 | 37 | 41 | 44 | 36 |
Smoking Status, % | ||||||||||
Never | 45 | 50 | 44 | 42 | 52 | 45 | 39 | 48 | 45 | 43 |
Former | 45 | 41 | 48 | 45 | 42 | 45 | 47 | 40 | 45 | 48 |
Current | 10 | 9 | 8 | 13 | 7 | 10 | 14 | 12 | 10 | 9 |
Alcohol Consumption, % | ||||||||||
None in Last Year | 51 | 49 | 48 | 54 | 50 | 49 | 55 | 51 | 48 | 53 |
Less than Once per Week | 21 | 22 | 21 | 20 | 22 | 22 | 19 | 21 | 21 | 22 |
1–7 Times per Week | 20 | 22 | 23 | 19 | 23 | 20 | 18 | 20 | 24 | 17 |
More than 1 per Day | 7 | 7 | 8 | 7 | 5 | 8 | 8 | 7 | 7 | 7 |
Medication Use, % | ||||||||||
NSAIDs | 22 | 22 | 20 | 22 | 25 | 22 | 20 | 20 | 24 | 24 |
Corticosteroids | 4 | 3 | 4 | 5 | 2 | 4 | 5 | 4 | 4 | 4 |
Statins | 12 | 14 | 13 | 13 | 12 | 12 | 13 | 11 | 12 | 15 |
Multivitamins | 18 | 18 | 19 | 17 | 25 | 14 | 15 | 19 | 19 | 17 |
Comorbid Conditions, % | ||||||||||
Cardiovascular Disease | 54 | 49 | 52 | 62 | 46 | 54 | 60 | 49 | 51 | 60 |
Pulmonary Disease (COPD, Chronic Bronchitis, Emphysema) | 13 | 12 | 13 | 14 | 10 | 12 | 16 | 13 | 12 | 13 |